The heart produces natriuretic peptides (ANP and BNP) that regulate blood pressure and fluid balance, but in heart failure their beneficial effects are diminished due to kidney resistance, creating a therapeutic opportunity for phosphodiesterase inhibitors.
The BNP paradoxIn heart failure, BNP levels measured in blood are high, but the forms detected by clinical assays may not be the physiologically active ones — meaning high BNP doesn't necessarily indicate effective cardiac protection.
What the researchers found
Under normal conditions, natriuretic peptides (ANP and BNP) are synthesized in response to atrial cardiomyocyte stretch and increase natriuresis, diuresis, and vascular permeability through cGMP-mediated signaling at specific receptors.
In heart failure, despite enhanced cardiac natriuretic peptide secretion, their beneficial effects are diminished due to renal resistance to NP action. A 'BNP paradox' exists: the BNP forms measured by current clinical assays may not represent the physiologically active forms, meaning high BNP levels in blood tests don't necessarily indicate effective peptide function. Inhibiting cyclic nucleotide phosphodiesterases (which degrade cGMP) represents a therapeutic strategy to improve natriuretic peptide system efficiency, with recent data supporting improved quality of life and prognosis in heart failure patients.
Why it matters
Heart failure affects millions worldwide and remains a leading cause of hospitalization and death. Understanding why the heart's own protective peptide system fails in heart failure — and how to restore it — could lead to better treatments. The BNP paradox also has diagnostic implications, as clinicians rely on BNP levels to assess heart failure severity, yet these measurements may not reflect actual peptide activity.
How the study worked
Narrative review of the physiology of cardiac natriuretic peptides, their signaling through cGMP pathways, the pathophysiology of natriuretic peptide resistance in heart failure, the BNP paradox, and the therapeutic potential of phosphodiesterase inhibitors to enhance natriuretic peptide signaling.
What this study cannot tell us
This is a narrative review that does not present new experimental data. The BNP paradox is described conceptually but the specific inactive BNP forms are not fully characterized. The therapeutic potential of PDE inhibitors is discussed based on recent data but without specific clinical trial results in the abstract. The review focuses primarily on ANP and BNP without detailed coverage of other natriuretic peptide family members (CNP, urodilatin).
How to read the evidence
This is a narrative review synthesizing established physiology and recent research on natriuretic peptides in heart failure. The underlying evidence spans decades of research from basic science to clinical trials, providing a well-established knowledge base.
When this study was published
Published in 2019, this review captures the understanding of natriuretic peptide biology during a period of active therapeutic development in heart failure, including the clinical success of sacubitril/valsartan.
The bigger picture
Natriuretic peptides are among the most clinically important peptides in medicine — BNP and NT-proBNP are routinely measured in emergency departments to diagnose heart failure. Understanding the disconnect between peptide levels and function in heart failure represents a frontier in cardiovascular medicine. The therapeutic approach of enhancing peptide signaling through PDE inhibition (rather than administering exogenous peptides) has already influenced drug development, including sacubitril/valsartan (Entresto), which inhibits the breakdown of natriuretic peptides.
Questions still open
- Can new assays that specifically measure active BNP forms improve heart failure diagnosis and monitoring?
- Which specific phosphodiesterase subtypes are the best therapeutic targets for enhancing natriuretic peptide signaling?
- Could restoring renal sensitivity to natriuretic peptides be a complementary therapeutic strategy to PDE inhibition?
Common questions
What are natriuretic peptides and what do they do?
Why don't natriuretic peptides work well in heart failure?
Read the original research
The Endocrine Function of the Heart: Physiology and Involvements of Natriuretic Peptides and Cyclic Nucleotide Phosphodiesterases in Heart Failure.
Journal of clinical medicine, 8(10)
Citation
Lugnier, Claire; Meyer, Alain; Charloux, Anne; Andrès, Emmanuel; Gény, Bernard; Talha, Samy. (2019). The Endocrine Function of the Heart: Physiology and Involvements of Natriuretic Peptides and Cyclic Nucleotide Phosphodiesterases in Heart Failure.. Journal of clinical medicine, 8(10). https://doi.org/10.3390/jcm8101746